한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제26권1호
  • /
  • Pages.84-95
  • /
  • 2016
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

심방세동 치료를 위한 미국과 유럽의 심박수 및 율동 조절 약물요법 가이드라인 비교 연구

A Comparative Study of USA and Europe Guidelines of Rate and Rhythm Control Pharmacotherapy in Atrial Fibrillation

  • 투고 : 2016.02.24
  • 심사 : 2016.03.15
  • 발행 : 2016.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: Atrial fibrillation (AF) guidelines have been published in the USA and Europe. Recently, the USA and Europe have updated their guidelines, respectively. These new AF guidelines help in addressing key management issues in clinical situations. This study, therefore, systematically compared guidelines for rate and rhythm control pharmacotherapy of patients with AF between the USA (American College of Cardiology and American Heart Association, ACC/AHA) and Europe (European Society of Cardiology, ESC). Methods: This study investigated and compared American guidelines (2014) and European guidelines (2010 and 2012). Results: Generally, there are four meaningful differences between ACC/AHA and ESC guidelines. Important differences are treatment classification system, level of recommendation, drug list, and dosage. In addition, ACC/AHA described pharmacokinetic drug interactions for antiarrhythmic drugs. ESC emphasized ECG and atrioventricular nodal slowing as feature of antiarrhythmic drugs. Conclusion: This research addresses important use of anti-arrhythmic drugs and movement to accept recent recommendations in Korea. For the successful application of the guidelines, a role of pharmacists is crucial in clinical situation.

키워드

참고문헌

  1. Gupta S, Tiruvoipati R, Green C. Atrial fibrillation and mortality in critically ill patients: a retrospective study. Am J Crit Care 2015;24(4):336-341. https://doi.org/10.4037/ajcc2015319
  2. Lee G, Campbell-Cole C. Recognising and managing atrial fibrillation in the community. Br J Community Nurs 2014;19(9):422-426. https://doi.org/10.12968/bjcn.2014.19.9.422
  3. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014;11(11):639-654. https://doi.org/10.1038/nrcardio.2014.118
  4. De Backer O, Arnous S, Ihlemann N, et al. Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. Open Heart 2014;1(1):e000020. https://doi.org/10.1136/openhrt-2013-000020
  5. Aryana A, Singh SK, Singh SM, et al. Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization. Heart Rhythm 2015;12(7):1431-1437. https://doi.org/10.1016/j.hrthm.2015.03.028
  6. Zhirov IV, Romanova NV, Tereshchenko SN, et al. Epidemiology and management of heart failure patients with atrial fibrillation. Kardiologiia 2015;55(3):91-96.
  7. Cutugno CL. Atrial fibrillation: updated management guidelines and nursing implications. Am J Nurs 2015;115(5):26-49. https://doi.org/10.1097/01.NAJ.0000465028.05223.39
  8. Berry E, Padgett H. Management of patients with atrial fibrillation: diagnosis and treatment. Nurs Stand 2012;26(22):47-56. https://doi.org/10.7748/ns.26.52.47.s47
  9. Moukabary T, Gonzalez MD. Management of atrial fibrillation. Med Clin North Am 2015;99(4):781-794. https://doi.org/10.1016/j.mcna.2015.02.007
  10. Greenberg H. Evidenced-based pharmacotherapy for rate control in atrial fibrillation. Crit Care Nurs Q 2013;36(2):237-243. https://doi.org/10.1097/CNQ.0b013e31828415dc
  11. Stead LG, Vaidyanathan L. Evidence-based emergency medicine/systematic review abstract. Rhythm control with electrocardioversion for atrial fibrillation and flutter. Ann Emerg Med 2009;54(5):745-747. https://doi.org/10.1016/j.annemergmed.2008.12.012
  12. Hargroves D, Ward L. Anticoagulants for stroke prevention in patients with atrial fibrillation. Br J Neurosci Nurs 2015:Supplement Stroke Clinical Updates:31-37.
  13. Saltman AE, Gillinov AM. Surgical approaches for atrial fibrillation. Cardiol Clin 2009;27(1):179-188. https://doi.org/10.1016/j.ccl.2008.09.012
  14. Chatterjee S, Sardar P, Lichstein E, et al. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol 2013;36(1): 122-133. https://doi.org/10.1111/j.1540-8159.2012.03513.x
  15. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann J, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015(3):N.PAG.
  16. Podrid PJ. Aggravation of arrhythmia: a complication of antiarrhythmic drugs. J Cardiovasc Electrophysiol 1993;4(3):311-319. https://doi.org/10.1111/j.1540-8167.1993.tb01233.x
  17. Chung R, Houghtaling PL, Tchou M, et al. Left ventricular hypertrophy and antiarrhythmic drugs in atrial fibrillation: impact on mortality. Pacing Clin Electrophysiol 2014;37(10):1338-1348. https://doi.org/10.1111/pace.12426
  18. Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol, in press.
  19. Estrada JC, Darbar D. Clinical use of and future perspectives on antiarrhythmic drugs. Eur J Clin Pharmacol 2008;64(12):1139-1146. https://doi.org/10.1007/s00228-008-0555-x
  20. Torres-Degayon, V, Torres-Murillo JM, Baena-Parejo MI, et al. Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department. J Clin Pharm Ther 2015;40(4):452-460. https://doi.org/10.1111/jcpt.12289
  21. Freeman JV, Simon DN, Go A, et al. Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 2015;8(4):393-402, https://doi.org/10.1161/CIRCOUTCOMES.114.001303
  22. Taylor CJ, Hodgkinson J, Hobbs FDR. Rhythm control agents and adverse events in patients with atrial fibrillation. Int J Clin Pract 2010;64(8):1069-1075. https://doi.org/10.1111/j.1742-1241.2010.02426.x
  23. Camm AJ, Yap YG. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol 1999;10(2):307-320. https://doi.org/10.1111/j.1540-8167.1999.tb00676.x
  24. Lee EJ, Kim J. Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation. J Clin Pharm Ther 2014;39(2):112-117. https://doi.org/10.1111/jcpt.12128
  25. Duray GZ, Torp-Pedersen C, Connolly SJ, et al. Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. J Cardiovasc Electrophysiol 2011;22(7):770-776. https://doi.org/10.1111/j.1540-8167.2010.02006.x
  26. Rosman J, Hoffmeister P, Reynolds M, et al. Possible proarrhythmia with dronedarone. J Cardiovasc Electrophysiol 2013;24(1):103-104. https://doi.org/10.1111/j.1540-8167.2012.02353.x
  27. Allen Lapointe NM, Lokhnygina Y, Sanders GD, et al. Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. Am Heart J 2013;166(5):871-878. https://doi.org/10.1016/j.ahj.2013.08.010
  28. Musco S, Conway EL, Kowey PR. Drug therapy for atrial fibrillation. Med Clin North Am 2008;92(1):121-141. https://doi.org/10.1016/j.mcna.2007.08.002
  29. Capucci A, Aschieri D, Villani G. Clinical pharmacology of antiarrhythmic drugs. Drugs Aging. 1998;13(1):51-70. https://doi.org/10.2165/00002512-199813010-00006
  30. Craig T, January L. Samuel W, et al. 2-13 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol 2014;64:2246-2280. https://doi.org/10.1016/j.jacc.2014.03.021
  31. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-2429. https://doi.org/10.1093/eurheartj/ehq278
  32. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-2747. https://doi.org/10.1093/eurheartj/ehs253
  33. Estes NA III, Halperin JL, Calkins H, et al. ACC/AHA/Physician consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter. Circulation 2008;117:1101-1120. https://doi.org/10.1161/CIRCULATIONAHA.107.187192
  34. Nieuwlaat, R, Connolly, SJ. Lenient rate control is as effective as strict rate control for preventing cardiovascular events in AF. ACP J Club 2010;153(2):JC2-4.
  35. Kowey PR, Breithardt G, Camm J, et al. Physician stated atrial fibrillation management in light of treatment guidelines: data from an international, observational prospective survey. Clin Cardiol 2010;33(3):172-178. https://doi.org/10.1002/clc.20737
  36. Curtis AB. Update on the clinical management of atrial fibrillation: guidelines and beyond. Postgrad Med 2011;123(6):7-20. https://doi.org/10.3810/pgm.2011.11.2491
  37. Rajagopalan B, Curtis AB. Management of atrial fibrillation: what is new in the 2014 ACC/AHA/HRS guideline? Postgrad Med 2015; 127(4):396-404. https://doi.org/10.1080/00325481.2015.1022495
  38. Phillips SE. Guideline-specific management of atrial fibrillation. Formulary 2010;45(5):156-164.
  39. Ariansen I, Abdelnoor M, Tveit A, et al. Guidelines' criteria for rate control in atrial fibrillation: are they useful? Scand Cardiovasc J 2010; 44(3):132-138. https://doi.org/10.3109/14017430903552632
  40. Dixon BJ, Bracha Y, Loecke SW, et al. Principal atrial fibrillation discharges by the new ACC/AHA/ESC classification. Arch Intern Med 2005;165(16):1877-1881. https://doi.org/10.1001/archinte.165.16.1877
  41. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16(1):6-14. https://doi.org/10.1093/europace/eut263
  42. Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC guidelines. Europace 2014;16(2):162-173. https://doi.org/10.1093/europace/eut274
  43. Kirchhof P, Curtis AB, Skanes AC, et al. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471-1474. https://doi.org/10.1093/eurheartj/ehs446
  44. Chen S, Liu S, Purerfellner H. Vernakalant as a novel anti-arrhythmic agent for converting of atrial fibrillation, molecular mechanism, updated clinical efficacy, and future development. Curr Pharm Des. in press.
  45. Conde D, Baranchuk A. Vernakalant for the conversion of atrial fibrillation: the new kid on the block? Ann Noninvasive Electrocardiol 2014;19(4):299-302. https://doi.org/10.1111/anec.12164
  46. Rudiger A, Breitenstein A, Arrigo M, et al. Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients. Crit Care Res Pract. in press.
  47. Camm AJ. The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A? Curr Cardiol Rev 2014; 10(4):309-314. https://doi.org/10.2174/1573403X10666140513103709
  48. Duggan ST, Scott LJ. Intravenous vernakalant: a review of its use in the management of recent-onset atrial ribrillation. Drugs 2011;71(2):237-252. https://doi.org/10.2165/10489050-000000000-00000
  49. Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs, 2009;69(7):757-774. https://doi.org/10.2165/00003495-200969070-00001
  50. Mao ZL, Townsend RW, Gao Y, et al. Population Pharmacokinetics of Vernakalant Hydrochloride Injection (RSD1235) in Patients With Atrial Fibrillation or Atrial Flutter. J Clin Pharmacol 2012;52(7): 1042-1053. https://doi.org/10.1177/0091270011408425
  51. Torp-Pedersen C, Crijns HJ, Gaudin C, et al. Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace 2011;13(8):1118-1126. https://doi.org/10.1093/europace/eur102
  52. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357(10):987-999. https://doi.org/10.1056/NEJMoa054686
  53. Rosa GM, Bianco D, Parodi A, et al. Pharmacokinetic and pharmacodynamic profile of dronedarone, a new antiarrhythmic agent for the treatment of atrial fibrillation. Expert Opin Drug Metab Toxicol 2014; 10(12):1751-1764. https://doi.org/10.1517/17425255.2014.974551
  54. Iannone P, Haupt E, Flego G, et al. Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. JAMA Intern Med 2014;174(4):625-629. https://doi.org/10.1001/jamainternmed.2013.14485
  55. Le Heuzey J, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study: Randomized, Double-Blind TrIal to Evaluate the Efficacy and Safety of DrOnedarone [400 mg bid] Versus AmiodaroNe [600 mg qd for 28 daYS, then 200 mg qd Thereafter] for at Least 6 mOnths for the Maintenance of Sinus Rhythm in Patients with AF. J Cardiovasc Electrophysiol 2010;21 (6):597-605. https://doi.org/10.1111/j.1540-8167.2010.01764.x
  56. Lee EJ, Kim J. Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation. J Clin Pharm Ther 2014;39(2):112-117. https://doi.org/10.1111/jcpt.12128
  57. Turgeon J, Murray KT, Roden DM. Effects of drug metabolism, metabolites, and stereoselectivity on antiarrhythmic drug action. J Cardiovasc Electrophysiol 1990;1(3):238-260. https://doi.org/10.1111/j.1540-8167.1990.tb01065.x
  58. Lin CY, Lin YJ, Lo LW, et al. Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart. Heart Rhythm 2015;12(7): 1490-1500. https://doi.org/10.1016/j.hrthm.2015.04.018
  59. CalO L, Martino A, Ciccaglioni A, et al. Upstream effect for atrial fibrillation: still a dilemma? Pacing Clin Electrophysiol 2011;34(1): 111-128. https://doi.org/10.1111/j.1540-8159.2010.02942.x
  60. Kumagai K. Upstream therapy for atrial fibrillation. Nihon Rinsho 2013;71(1):86-90.
  61. Goette A, Hammwohner M, Bukowska A. Upstream therapy for atrial fibrillation. Herzschrittmacherther Elektrophysiol 2014;25(1):33-40. https://doi.org/10.1007/s00399-014-0303-0
  62. Danelich IM, Reed BN, Hollis IB, et al. Clinical update on the management of atrial fibrillation. Pharmacotherapy 2013;33(4):422-446. https://doi.org/10.1002/phar.1217
  63. Pandya B, Lambiase PD. An avoidable antiarrhythmic side effect. Br J Hosp Med (Lond), 2006;67(1):M14-15. https://doi.org/10.12968/hmed.2006.67.Sup1.20338
  64. Shu J, Zhou J, Patel C, et al. Pharmacotherapy of cardiac arrhythmiasbasic science for clinicians. Pacing Clin Electrophysiol 2009;32(11): 1454-1465. https://doi.org/10.1111/j.1540-8159.2009.02526.x
  65. Heijman J, Voigt N, Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol 2013;9(1):71-88. https://doi.org/10.2217/fca.12.78
  66. Darbar D, Roden DM. Future of antiarrhythmic drugs. Curr Opin Cardiol 2006;21(4):361-337. https://doi.org/10.1097/01.hco.0000231407.61683.05